OralTox Oral fluid Drug Test
Device Facts
| Record ID | K181305 |
|---|---|
| Device Name | OralTox Oral fluid Drug Test |
| Applicant | Premier Biotech, Inc. |
| Product Code | DJC · Clinical Toxicology |
| Decision Date | Sep 20, 2018 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.3610 |
| Device Class | Class 2 |
Indications for Use
The OralTox® Oral Fluid Drug Test is a competitive binding, lateral flow immunochromatographic assay for the qualitative and simultaneous detection of amphetamine, cocaine, marijuana (THC), methamphetamine, opiates, phencyclidine, oxycodone and methadone in human oral fluid at the cut-off concentrations listed below and their metabolites: Drug (Identifier) Calibrator Cut-off level Amphetamine (AMP) D-Amphetamine 50 ng/mL Cocaine (COC) Benzoylecgonine 20 ng/mL Cannabinoids (THC) Delta-8-Tetrahydrocannabinol 40 ng/mL Methamphetamine (MET) D-Methamphetamine 50 ng/mL Opiates (OPI) Morphine 40 ng/mL Phencyclidine (PCP) Phencyclidine 10 ng/mL Oxycodone (OXY) Oxycodone 20 ng/mL Methadone (MTD) Methadone 30 ng/mL The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method. It is not intended to detect intermittent dosing of oxycodone. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive. For in vitro diagnostic use only. The tests are intended for prescription use.
Device Story
OralTox® is a single-use, lateral flow immunochromatographic test cup for qualitative drug screening in human oral fluid. Device includes integrated collection sponge and saturation indicator strip; indicator turns red when sufficient sample volume is collected for testing and potential laboratory confirmation. Operation involves collecting oral fluid via sponge; fluid migrates via capillary action through test strips. Principle is competitive binding: target drugs below cut-off allow antibody-coated particles to bind to immobilized drug-conjugate, forming a visible test line; drug concentrations above cut-off saturate binding sites, preventing line formation. Control line confirms proper test performance. Used at point-of-care by healthcare professionals. Results are visually read. Preliminary positive results require confirmation via LC-MS/MS. Benefits include rapid, on-site screening for multiple drug analytes to inform clinical decision-making.
Clinical Evidence
No clinical studies were performed. Performance was established via bench testing, including precision/reproducibility studies across three sites and method comparison studies. Method comparison evaluated 932 samples (434 for oxycodone, 498 for methadone) against LC-MS/MS reference method. Results showed high concordance with LC-MS/MS; discordant results were analyzed. Analytical specificity, cross-reactivity, and interference studies (exogenous substances, pH, smoking, hemoglobin) were conducted to validate performance for the new analytes.
Technological Characteristics
Lateral flow immunochromatographic assay. Single-use test cup with integrated collection sponge and saturation indicator. Qualitative, visually read. No energy source required. Materials include monoclonal mouse antibodies. Analyte cut-offs: AMP 50 ng/mL, COC 20 ng/mL, THC 40 ng/mL, MET 50 ng/mL, OPI 40 ng/mL, PCP 10 ng/mL, OXY 20 ng/mL, MTD 30 ng/mL. Stable for 24 months at 4-30°C.
Indications for Use
Indicated for qualitative, simultaneous detection of Amphetamine, Cocaine, Marijuana (THC), Methamphetamine, Opiates, Phencyclidine, Oxycodone, and Methadone in human oral fluid. For prescription use. Not intended to detect intermittent Oxycodone dosing.
Regulatory Classification
Identification
A methamphetamine test system is a device intended to measure methamphetamine, a central nervous system stimulating drug, in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of methamphetamine use or overdose.
Special Controls
*Classification.* Class II (special controls). A methamphetamine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
Predicate Devices
- OralTox® Oral Fluid Drug Test (k171403)
Submission Summary (Full Text)
{0}
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONS
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k181305
B. Purpose for Submission:
Modification of a previously cleared device to include new test analytes, methadone and oxycodone.
C. Measurands:
Amphetamine, cocaine, cannabinoids, methamphetamine, morphine, phencyclidine, oxycodone and methadone.
D. Type of Test:
Qualitative, lateral flow immunochromatographic
E. Applicant:
Premier Biotech, Inc.
F. Proprietary and Established Names:
OralTox® Oral Fluid Drug Test
G. Regulatory Information:
| Product Code | Classification | Relation Section | Panel |
| --- | --- | --- | --- |
| DKZ | Class II | 21CFR 862.3100, Amphetamine Test System | Toxicology (91) |
| DIO | Class II | 21 CFR 862.3250, Cocaine and metabolites TEST System | Toxicology (91) |
| LDJ | Class II | 21 CFR 862.3870, Cannabinoids Test System | Toxicology (91) |
| DJC | Class II | 21 CFR 862.3610, Methamphetamine Test System | Toxicology (91) |
| LCM | Class II | Unclassified, Enzyme immunoassay Phencyclidine | Toxicology (91) |
| DJG | Class II | 21 CFR 862.3650, Opiate Test System | Toxicology (91) |
1
{1}
| DJR | Class II | 21 CFR, 862.3610 Methadone Test System | Toxicology (91) |
| --- | --- | --- | --- |
### H. Intended Use:
#### 1. Intended use(s):
Refer to Indications for Use below.
#### 2. Indication(s) for use:
The OralTox \( ^{®} \) Oral Fluid Drug Test is a competitive binding, lateral flow immunochromatographic assay for the qualitative and simultaneous detection of amphetamine, cocaine, marijuana (THC), methamphetamine, opiates, phencyclidine, oxycodone and methadone in human oral fluid at the cut-off concentrations listed below and their metabolites:
| Drug (Identifier) | Calibrator | Cut-off level |
| --- | --- | --- |
| Amphetamine (AMP) | D-Amphetamine | 50 ng/mL |
| Cocaine (COC) | Benzoylecgonine | 20 ng/mL |
| Cannabinoids (THC) | Delta-8-Tetrahydrocannabinol | 40 ng/mL |
| Methamphetamine (MET) | D-Methamphetamine | 50 ng/mL |
| Opiates (OPI) | Morphine | 40 ng/mL |
| Phencyclidine (PCP) | Phencyclidine | 10 ng/mL |
| Oxycodone (OXY) | Oxycodone | 20 ng/mL |
| Methadone (MTD) | Methadone | 30 ng/mL |
The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method. It is not intended to detect intermittent dosing of oxycodone. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.
For in vitro diagnostic use only. The tests are intended for prescription use.
#### 3. Special conditions for use statement(s):
For prescription point-of-care use.
#### 4. Special instrument requirements:
Not applicable; the device is a visually-read single use device.
2
{2}
# I. Device Description:
The OralTox® Oral Fluid Drug Test is an immunochromatographic assay that uses a lateral flow system for the qualitative detection of amphetamine, cocaine, cannabinoids, methamphetamine, morphine, phencyclidine, oxycodone and methadone (target analytes) in human oral fluid.
The products are single-use in vitro diagnostic devices. Each test kit contains a test cup, a package insert and a sample collection sponge. Each test device is sealed with a desiccant in an aluminum pouch.
The device has a built-in sample collection tool, including collection swab and sponge, as well as a saturation indicator strip. The saturation indicator strip turns red when a volume of oral fluid has been collected that is adequate to both run the OralTox® test and to conduct confirmation testing at a laboratory if the result is a presumptive positive.
OralTox® Oral Fluid Drug Tests are the first step in a two-step process. The second step is to send the sample for confirmatory laboratory testing using a more specific method (e.g., LC-MS/MS) if preliminary positive results are obtained.
# J. Substantial Equivalence Information:
1. Predicate device name(s):
OralTox® Oral Fluid Drug Test
2. Predicate 510(k) number(s):
k171403
3. Comparison with predicate:
| Similarities | | |
| --- | --- | --- |
| Item | Proposed device | Predicate device |
| Intended Use | Same | Preliminary Drug screening test for the qualitative detection of drug analytes in oral fluid (human saliva) For In Vitro Diagnostic Use |
| Drug analytes detected | D-Amphetamine Cocaine Delta-9-Tetrahydrocannabinol D-Methamphetamine Morphine Phencyclidine Methadone | D-Amphetamine Cocaine Delta-9-Tetrahydrocannabinol D-Methamphetamine Morphine Phencyclidine |
3
{3}
| Similarities | | |
| --- | --- | --- |
| Item | Proposed device | Predicate device |
| | Oxycodone | |
| Methodology | Same | Competitive binding, lateral flow immunochromatographic assays based on the principle of antigen antibody immunochemistry |
| Type of Test | Same | Qualitative |
| Specimen Type | Same | Human Oral fluid |
| Cut-offs | AMP 50 ng/mL COC 20 ng/mL THC 40 ng/mL MET 50 ng/mL OPI 40 ng/mL PCP 10 ng/mL OXY 20 ng/mL MTD 30 ng/mL | AMP 50 ng/mL COC 20 ng/mL THC 40 ng/mL MET 50 ng/mL MOP 40 ng/ML PCP 10 ng/mL |
| Differences | | |
| Item | Device | Predicate |
| Drug analytes detected | D-Amphetamine Cocaine Delta-9-Tetrahydrocannabinol D-Methamphetamine Morphine Phencyclidine Methadone Oxycodone | D-Amphetamine Cocaine Delta-9-Tetrahydrocannabinol D-Methamphetamine Morphine Phencyclidine |
| Number of analytes detected | 8 | 6 |
### K. Standard/Guidance Document Referenced (if applicable):
None Referenced.
### L. Test Principle:
The OralTox® Oral Fluid Drug Test is an immunochromatographic assay that uses a lateral flow system for the qualitative detection of amphetamine, cocaine, cannabinoids, methamphetamine, morphine, and phencyclidine, methadone, and oxycodone, (target analytes) in human oral fluid. The tests are lateral flow chromatographic immunoassays. During testing, an oral fluid specimen migrates upward by capillary action. If target drugs present in the oral fluid specimen are below the cut-off concentration, it will not saturate the
4
{4}
binding sites of its specific monoclonal mouse antibody coated on the particles. The antibody-coated particles will then be captured by immobilized drug-conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the target drug level exceeds its cut-off-concentration because it will saturate all the binding sites of the antibody coated on the particles. A band should form in the control region of the devices regardless of the presence of drug or metabolite in the sample to indicate that the tests have been performed properly.
### M. Performance Characteristics (if/when applicable):
#### 1. Analytical performance:
The analytical performance of the device for the measurement of d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine (MET), morphine (OPI), and phencyclidine (PCP), was reviewed in k171403. Please see the decision summary for k171403 for information regarding performance of these analytes.
##### a. Precision/Reproducibility:
Precision-reproducibility-cut-off studies were carried out for samples with concentrations of -100% cut-off, -75% cut-off, -50% cut-off, -25% cut-off, cut-off, +25% cut-off, +50% cut-off, +75% cut-off and +100% cut-off. Testing was repeated across three sites. These samples were prepared by spiking drug in negative oral fluid samples. The sponsor has stated that each drug concentration was confirmed by LC-MS/MS. All sample aliquots were blindly labeled by the person who prepared the samples and didn't take part in the sample testing. For each concentration, tests were performed two runs per day for 10 days per device lot in a randomized order. The sponsor provided the following summaries:
| Methadone | -100% cut-off | -75% cut-off | -50% cut-off | -25% cut-off | cut-off | +25% cut-off | +50% cut-off | +75% cut-off | +100% cut-off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 49+/11- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 48+/12- | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 50+/10- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Oxycodone | -100% cut-off | -75% cut-off | -50% cut-off | -25% cut-off | cut-off | +25% cut-off | +50% cut-off | +75% cut-off | +100% cut-off |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Lot 1 | 60-/0+ | 60-/0+ | 60-/0+ | 55-/5+ | 50+/10- | 55+/5- | 60+/0- | 60+/0- | 60+/0- |
| Lot 2 | 60-/0+ | 60-/0+ | 60-/0+ | 54-/6+ | 49+/11- | 56+/4- | 60+/0- | 60+/0- | 60+/0- |
| Lot 3 | 60-/0+ | 60-/0+ | 60-/0+ | 56-/4+ | 49+/11- | 57+/3- | 60+/0- | 60+/0- | 60+/0- |
5
{5}
The device has been developed with the following cut-offs:
| Calibrator | Cut-off (ng/mL) |
| --- | --- |
| D-methamphetamine | 50 |
| Cocaine | 20 |
| Morphine | 40 |
| D-amphetamine | 50 |
| Phencyclidine | 10 |
| Delta-9-tetrahydrocannabinol | 40 |
| Methadone | 30 |
| Oxycodone | 20 |
Sample Volume:
A sample volume study was conducted in k171403 to confirm the reproducibility of adequate sample volume collection by the device and found to be acceptable.
b. Linearity/assay reportable range:
Not applicable. These devices are intended for qualitative use only.
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Accelerated stability and real time studies have been conducted for the device. Protocols and acceptance criteria were described and found to be acceptable. The manufacturer claims that when stored un-opened at 4-30 °C, the device is stable for 24 months.
### Sample Recovery
Volume recovery:
A sample volume recovery study was provided in k171403 and found to be acceptable.
Analyte recovery:
In order to confirm that preliminary positive results can be adequately measured via confirmation testing after being subject to the temperature conditions required for shipping and storage, negative oral fluid samples in glass bottles were spiked with a single analyte/bottle to concentrations approximately -50% and +50% of the cut-off. Samples were spiked using known standards. Each drug concentration was confirmed by LC-MS/MS. The samples were transferred to OralTox® devices using the collection sponges. For each of 3 storage conditions (-20°C, 20-25°C, and 40°C), 12 devices were used (4 devices from each of 3 lots. For each device, drug was measured by LC-MS/MS at time zero and the devices containing the specimens were
6
{6}
stored under the specified condition. Drug in the devices stored at 20-25°C and 40°C was measured by LC-MS/MS at two (2) days, and drug in the devices stored at -20°C was measured by LC-MS/MS at 90 days.
The minimum and maximum recovery from 12 devices per lot per storage condition is shown below. Analyte recovery for d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine (MET), morphine (OPI), and phencyclidine (PCP) was provided in k171403.
Room Temperature 20-25°C (two day storage)
| | OXY +50 | OXY -50 | MTD +50 | MTD -50 |
| --- | --- | --- | --- | --- |
| Max | 99 | 99 | 100 | 99 |
| Min | 91 | 91 | 92 | 92 |
40 °C (two day storage)
| | OXY +50 | OXY -50 | MTD +50 | MTD -50 |
| --- | --- | --- | --- | --- |
| Max | 98 | 99 | 100 | 93 |
| Min | 92 | 93 | 92 | 97 |
-20 °C (90 day storage)
| | OXY +50 | OXY -50 | MTD +50 | MTD -50 |
| --- | --- | --- | --- | --- |
| Max | 100 | 98 | 101 | 105 |
| Min | 93 | 93 | 93 | 91 |
Results indicate that samples may be stored at room temperature for up to two days, elevated temperature for up to do days (40 °C), and for up to 90 days at – 20 °C, prior to confirmatory testing.
# d. Detection limit:
See Precision/Reproducibility section in M.1.a above.
# e. Analytical specificity:
To test cross reactivity, drug metabolites and other components that may be present in oral fluid samples were tested using three lots of the OralTox® device. The following is a summary of the cross-reactivity study. A cross-reactivity study for d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine (MET), morphine (OPI), and phencyclidine (PCP) was provided in k171403.
7
{7}
| Oxycodone (Cut-off=20 ng/mL) | Result Positive at (ng/mL) | % Cross-Reactivity |
| --- | --- | --- |
| Oxycodone | 20 | 100% |
| Hydrocodone | 1000 | 2% |
| Hydromorphone | 6250 | 0.3% |
| Naloxone | 6250 | 0.3% |
| Oxymorphone | 1000 | 2% |
| Dihydrocodeine | Negative at 10000 | <0.2% |
| Buprenorphine | Negative at 10000 | <0.2% |
| 6-AM | Negative at 10000 | <0.2% |
| Codeine | Negative at 10000 | <0.2% |
| Heroin | Negative at 10000 | <0.2% |
| Morphine | Negative at 10000 | <0.2% |
| Morphine -3-β-d- | Negative at 10000 | <0.2% |
| Ethylmorphine | Negative at 10000 | <0.2% |
| Methadone (Cut-off=30 ng/mL) | Result Positive at(ng/ml) | % Cross-Reactivity |
| --- | --- | --- |
| Alpha-methadol | 125 | 24% |
| Doxylamine | 12500 | 0.24% |
| 2-Ethylidene-1,5-dimethyl-3,3-diphenyl pyrrolidine (EDDP) | 10000 | 0.3% |
| Phencyclidine | 12500 | 0.24% |
| 2-Ethyl-5-methyl-3,3-diphenylpyrroline (EMDP) | 100000 | 0.03% |
| LAAM | 10000 | 0.3% |
**Exogenous Interference:** Potential interference from structurally unrelated compounds were tested by spiking the potentially interfering compound at a concentration of 10 ug/mL into drug free oral fluid or fluid containing the target drug with concentrations of 50% below and 50% above cut-off level. The following compounds were found not to interfere with test results at a concentration of 10ug/mL for all samples tested. An exogenous interference study for D-Amphetamine (AMP), Cocaine (COC), Delta-8-Tetrahydrocannabinol (THC), D-Methamphetamine (MET), Morphine (OPI), and Phencyclidine (PCP) was provided in k171403.
| Acetaminophen | Digoxin | Nicotinamide |
| --- | --- | --- |
| Acetylcodeine | Dihydrocodeine | Nicotine |
| Allobarbital | diltiazem HCl | Noscapine |
| Alprazolam | Diphenhydramine HCl | Omeprazole |
| Amobarbital | DL-Propranolol | Papaverine |
8
{8}
| Apomorphine | Doxylamine | Pentazocine |
| --- | --- | --- |
| Atenolol | Ecgonine methylester | Phentermine |
| Atropine | Estradiol | Phenylpropanolamine |
| Baclofen | Estrone | Phenytoin |
| Benzocaine | Fluconazole | Pioglitazone HCl |
| Butabarbital | Furosemide | Prednisolone |
| Caffeine | Hexobarbital | Prednisone |
| Cannabidiol | Hydrochlorothiazide | Procainamide HCl |
| Carbamazepine | Ibuprofen | Procaine HCL |
| Chlordiazepoxide | Imipramine | Promethazine |
| Chlorpromazine | Lamotrigine | Quinine HCl |
| Cimetidine | Levetiracetam | R,r(-)-pseudoephedrine |
| Citalopram HBr | Lidocaine | Salicylic Acid |
| Clobazam | Lormetazepam | Sertraline HCL |
| Clomipramine | L-thyroxine | Simvastin |
| Clonazepam | Metformin HCl | Theophylline |
| Clonidine | Methylphenidate HCl | Thiamine |
| Clopidogrel bisulfate | Metoprolol | Topiramate |
| Cortisol | Metronidazole | Valproic acid |
| Cotinine | Montelukast sodium salt | Verapamil |
| D,l-Salbutamol | Naloxone | Zonisamide |
| Deoxycorticosterone | Naltrexone | |
| Dextromethorphan | Naproxen | |
The following potential interference from substances commonly present in oral fluid were evaluated by spiking into drug free oral fluid or oral fluid containing the target drug with concentrations of 50% below and 50% above cut-off level to a concentration of 5%: alcohol, baking soda, chewing gum, coffee, cola, cough syrup, cranberry juice, food coloring (blue, green, and red), methanol cough drops, milk, mouthwash, MSG, orange juice, salt, sugar, tea, toothpaste, and tomatoes. None of these substances showed any interference with the detection of any analyte (OXY, MTD) using the device. A study testing these substances for interference to detection of d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine (MET), morphine (OPI), and phencyclidine (PCP) was provided in k171403.
Potential interference from cigarette smoking, was evaluated by asking a participant to smoke a cigarette. After 15 minutes of smoking, an oral fluid sample was collected and spiked with each drug at concentrations of cut-off +/- 50%. No interference with the detection of any analyte (OXY, MTD) using the device was observed. A study testing potential interference from cigarette smoking to detection of d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine
9
{9}
(MET), morphine (OPI), and phencyclidine (PCP) was provided in k171403.
Potential interference from hemoglobin was evaluated by adding it to drug free oral fluid or oral fluid containing the target drug with concentrations of 50% above and 50% below cut-off level to a concentration of 100ug/mL. No interference with the detection of any analyte (OXY, MTD) using the device was observed. A study testing for potential interference from hemoglobin to detection of d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine (MET), morphine (OPI), and phencyclidine (PCP) was provided in k171403.
Effect of oral fluid pH: To investigate the effect of oral fluid pH, oral fluid samples with pH 4 to 9 were spiked with target drugs at 50% below and 50% above cut-off levels. These samples were tested using three lots of the device. Results were all positive for samples (OXY, MTD) at and above +50% cut-off and all negative for samples at and below -50% Cut-Off. A study to test the potential interference due to pH for d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine (MET), morphine (OPI), and phencyclidine (PCP) was provided in k171403.
There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results, e.g., technical or procedural errors.
# f. Assay cut-off:
Characterization of how the device performs analytically around the claimed cut-off concentration appears in the precision section, M.1.a., above.
# 2. Comparison studies:
# a. Method comparison:
Method comparison studies for the OralTox® Oral fluid Drug Test were performed, testing a total of 932 samples. 434 samples were evaluated for oxycodone at four sites, and 498 samples were evaluated for methadone at four sites. Each site utilized three operators. Device results were compared to LC-MS/MS results. The results are presented in the tables below. A method comparison study for d-amphetamine (AMP), cocaine (COC), delta-8-tetrahydrocannabinol (THC), d-methamphetamine (MET), morphine (OPI), and phencyclidine (PCP) was provided in k171403.
10
{10}
### Oxycodone
| Concentration (% of Cut-off) by LC/MS | Number of samples | OralTox Results | | The percentage of correct results (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug free (0%) | 152 | 0 | 152 | 100 |
| <50% of cut-off | 47 | 0 | 47 | 100 |
| 50% of cut-off to cut-off | 32 | 5 | 27 | 84.4 |
| Cut-off to 150% of cut-off | 29 | 25 | 4 | 86.2 |
| >150% of cut-off | 174 | 174 | 0 | 100 |
### Discordant results (oxycodone)
| Sample | LC/MS Result | Device Result |
| --- | --- | --- |
| 1 | 18.0 | Positive |
| 2 | 17.2 | Positive |
| 3 | 19.05 | Positive |
| 4 | 18.23 | Positive |
| 5 | 18.52 | Positive |
| 6 | 23.29 | Negative |
| 7 | 22.04 | Negative |
| 8 | 22.4 | Negative |
| 9 | 22.34 | Negative |
### Methadone
| % of Cut-off | Number of samples | OralTox Results | | The percentage of correct results (%) |
| --- | --- | --- | --- | --- |
| | | No. of Positive | No. of Negative | |
| Drug free (0%) | 277 | 0 | 277 | 100 |
| <50% of cut-off | 13 | 0 | 13 | 100 |
| 50% of cut-off to cut-off | 20 | 4 | 16 | 80 |
| cut-off to 150% of cut-off | 15 | 13 | 2 | 87 |
| >150% of cut-off | 173 | 173 | 0 | 100 |
11
{11}
Discordant results (methadone)
| Sample Number | LC/MS Result | Device Result |
| --- | --- | --- |
| 1 | 26.9 | Positive |
| 2 | 27.85 | Positive |
| 3 | 28.26 | Positive |
| 4 | 28.82 | Positive |
| 5 | 31.07 | Negative |
| 6 | 31.29 | Negative |
b. Matrix comparison:
Not applicable. These devices are for use with oral fluid samples only.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
Not applicable.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
12
